Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
NFKB1
REST API REST API
Homo sapiens
NFKB1 is differentially expressed in 255 experiments: 116 organism parts: brain, liver, ... (114 more);, 171 disease states: normal, control, ... (169 more);, 90 cell types 291 cell lines 41 compound treatments and 66 other conditions.
Synonyms p50, NFkappaB, p105, NF-kappaB, NFKB-p50, KBF1
Orthologs Nfkb1 (Mus musculus)   NFKB1 (Gallus gallus)   Nfkb1 (Rattus norvegicus)   NFKB1 (Bos taurus)   Q4H348_CIOIN (Ciona intestinalis)   Rel (Drosophila melanogaster)   nfkb1 (Xenopus laevis)   NFKB1_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term Toll signaling pathway, cytosol, response to oxidative stress, DNA binding, negative regulation of transcription, DNA-dependent, response to copper ion, protein binding, apoptosis, regulation of transcription, DNA-dependent, cytoplasm, double-stranded DNA binding, innate immune response, protein complex, anti-apoptosis, transcription from RNA polymerase II promoter, sequence-specific DNA binding, protein dimerization activity, positive regulation of transcription from RNA polymerase II promoter, response to bacterium, nucleus, protein homodimerization activity, positive regulation of NF-kappaB transcription factor activity, nucleoplasm, negative regulation of transcription from RNA polymerase II promoter, signal transduction, positive regulation of transcription, DNA-dependent, mitochondrion, heat shock protein binding, toll-like receptor 4 signaling pathway, negative regulation of cytokine production, T cell receptor signaling pathway, positive regulation of macrophage derived foam cell differentiation, negative regulation of interleukin-12 biosynthetic process, toll-like receptor signaling pathway, I-kappaB/NF-kappaB complex, cellular response to mechanical stimulus, positive regulation of lipid storage, negative regulation of cholesterol transport, negative regulation of calcidiol 1-monooxygenase activity, positive regulation of canonical Wnt receptor signaling pathway, toll-like receptor 3 signaling pathway, inflammatory response, nerve growth factor receptor signaling pathway, toll-like receptor 2 signaling pathway, MyD88-dependent toll-like receptor signaling pathway, cellular response to interleukin-1, sequence-specific DNA binding transcription factor activity, MyD88-independent toll-like receptor signaling pathway, negative regulation of vitamin D biosynthetic process, membrane protein intracellular domain proteolysis, negative regulation of cellular protein metabolic process, transcription regulatory region DNA binding, nucleic acid binding transcription factor activity, toll-like receptor 1 signaling pathway, regulatory region DNA binding
InterPro Term Ankyrin_rpt, Ankyrin_rpt-contain_dom, RHD, NF_Rel_dor, Death, IPT_TIG_rcpt
UniProt Accession D6RDI9, D6RC45, D6RH30, D6RF93, P19838
Search EB-eye ENSG00000109320
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-AFMX-5, E-GEOD-803, E-MEXP-1251, E-MTAB-24, ... (19 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (32 experiments)

Factor Value U/D Experiments
BT-474
2
E-GEOD-5823, E-GEOD-3529
MOLT4
2
E-MTAB-37, E-MTAB-62
PC3
2
E-MEXP-2034, E-GEOD-5258
SW480
2
E-MEXP-1014, E-GEOD-18005
K562
1
2
E-GEOD-24147, E-GEOD-96, E-MTAB-37
GCT
1
E-MTAB-37
285 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-22373, E-GEOD-21668, E-GEOD-19397, E-GEOD-20677, ... (39 experiments)

Factor Value U/D Experiments
macrophage
2
E-GEOD-22373, E-GEOD-5099
CD14+ monocyte
2
E-AFMX-5, E-TABM-145
2
E-TABM-145, E-TABM-130
721 B lymphoblast
2
E-AFMX-5, E-TABM-145
induced pluripotent stem cell
2
E-GEOD-18265, E-GEOD-18147
human embryonic stem cell
1
2
E-GEOD-18265, E-GEOD-18147, E-GEOD-20033
84 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-TABM-15, E-GEOD-5370, E-MTAB-62, ... (52 experiments)

Factor Value U/D Experiments
glioblastoma
3
E-GEOD-4290, E-MTAB-37, E-MTAB-62
control
1
3
E-GEOD-21912, E-GEOD-8121, E-GEOD-20295, E-GEOD-20602
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-96
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
chronic lymphocytic leukemia
2
E-GEOD-2466, E-MTAB-37
neuroblastoma
2
E-MTAB-37, E-MTAB-62
165 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-5741, E-GEOD-3720, E-TABM-868, E-MEXP-1958, ... (26 experiments)

Factor Value U/D Experiments
lipopolysaccharide
4
E-TABM-868, E-MEXP-1958, E-GEOD-3720, E-GEOD-2706
none
4
7
E-MEXP-1230, E-TABM-868, E-MEXP-1958, E-GEOD-2706, E-GEOD-2624, ... (11 experiments)
control
2
E-GEOD-3284, E-GEOD-5339
ox-LDL
1
E-GEOD-5741
lipopolysaccharide and R848
1
E-GEOD-2706
actinomycin D
1
E-GEOD-6400
35 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-2171, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-MEXP-1251, E-GEOD-21589, ... (7 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-GEOD-20033

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-GEOD-3325, E-MTAB-69, E-TABM-147, ... (6 experiments)

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-GEOD-7578, E-GEOD-20847, E-GEOD-361

Genotype
studied in E-GEOD-1923, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-7011, E-TABM-127, E-GEOD-20540, E-MEXP-1446, E-GEOD-22278, ... (7 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-GEOD-1926, E-MEXP-2069, ... (33 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-9723, E-GEOD-980, ... (9 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-12662

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-426

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-26495, E-GEOD-22309, E-GEOD-21750, E-GEOD-1460, E-GEOD-17636, ... (7 experiments)

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

Replicate
studied in E-GEOD-18791

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-GEOD-1676, E-GEOD-3697, E-MEXP-1857, E-MEXP-2759 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-2466

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-19246, E-GEOD-12198

Tumor grading
studied in E-GEOD-4290

Vehicle
studied in E-GEOD-5258

Processing time: 0.445 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM